Chicago-based GE HealthCare has partnered with CDL Nuclear Technologies to distribute Flyrcado, a new cardiac PET imaging agent, to hospitals and outpatient practices nationwide.
The agent is designed to improve diagnosis of coronary artery disease and will be available in both office-based cardiology settings and hospital imaging centers, according to a Sept. 8 news release.
CDL Nuclear Technologies works with about 225 sites across the U.S., supporting more than 200,000 patient procedures each year.
The rollout of Flyrcado is set to begin in late 2025 and expand further in 2026, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
